Viking Therapeutics, Inc. (NASDAQ:VKTX - Get Free Report)'s share price was down 5.8% during trading on Monday . The company traded as low as $24.58 and last traded at $24.51. Approximately 1,943,881 shares traded hands during trading, a decline of 52% from the average daily volume of 4,033,500 shares. The stock had previously closed at $26.01.
Analysts Set New Price Targets
A number of equities research analysts recently commented on VKTX shares. Morgan Stanley decreased their price objective on Viking Therapeutics from $105.00 to $102.00 and set an "overweight" rating for the company in a research note on Thursday, April 24th. Cantor Fitzgerald raised Viking Therapeutics to a "strong-buy" rating in a research note on Tuesday, April 29th. HC Wainwright reaffirmed a "buy" rating and set a $102.00 price objective on shares of Viking Therapeutics in a research note on Wednesday. The Goldman Sachs Group started coverage on Viking Therapeutics in a research note on Tuesday, April 8th. They set a "neutral" rating and a $30.00 price objective for the company. Finally, Truist Financial reaffirmed a "buy" rating and set a $75.00 price objective (down from $95.00) on shares of Viking Therapeutics in a research note on Monday, April 28th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $87.15.
Get Our Latest Report on Viking Therapeutics
Viking Therapeutics Price Performance
The stock has a market capitalization of $3.16 billion, a price-to-earnings ratio of -24.50 and a beta of 0.65. The business has a 50 day simple moving average of $27.14 and a 200-day simple moving average of $30.61.
Viking Therapeutics (NASDAQ:VKTX - Get Free Report) last posted its quarterly earnings data on Wednesday, April 23rd. The biotechnology company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.10). Viking Therapeutics's quarterly revenue was up .0% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.26) earnings per share. As a group, equities analysts predict that Viking Therapeutics, Inc. will post -1.56 earnings per share for the current year.
Insider Transactions at Viking Therapeutics
In other news, Director Sarah Kathryn Rouan acquired 1,240 shares of Viking Therapeutics stock in a transaction dated Monday, March 31st. The stock was bought at an average cost of $24.15 per share, with a total value of $29,946.00. Following the completion of the transaction, the director now directly owns 1,240 shares of the company's stock, valued at approximately $29,946. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.10% of the stock is owned by insiders.
Institutional Trading of Viking Therapeutics
Institutional investors and hedge funds have recently bought and sold shares of the stock. Quarry LP raised its holdings in Viking Therapeutics by 1,621.4% during the first quarter. Quarry LP now owns 1,205 shares of the biotechnology company's stock worth $29,000 after acquiring an additional 1,135 shares in the last quarter. Parallel Advisors LLC raised its holdings in Viking Therapeutics by 64.8% during the first quarter. Parallel Advisors LLC now owns 1,363 shares of the biotechnology company's stock worth $33,000 after acquiring an additional 536 shares in the last quarter. FIL Ltd raised its holdings in Viking Therapeutics by 116.8% during the fourth quarter. FIL Ltd now owns 1,203 shares of the biotechnology company's stock worth $48,000 after acquiring an additional 648 shares in the last quarter. NBC Securities Inc. raised its holdings in Viking Therapeutics by 222,100.0% during the first quarter. NBC Securities Inc. now owns 2,222 shares of the biotechnology company's stock worth $53,000 after acquiring an additional 2,221 shares in the last quarter. Finally, CIBC Private Wealth Group LLC raised its holdings in Viking Therapeutics by 170.2% during the fourth quarter. CIBC Private Wealth Group LLC now owns 1,351 shares of the biotechnology company's stock worth $55,000 after acquiring an additional 851 shares in the last quarter. Institutional investors own 76.03% of the company's stock.
Viking Therapeutics Company Profile
(
Get Free Report)
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
Further Reading
Before you consider Viking Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Viking Therapeutics wasn't on the list.
While Viking Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
